問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Infectious Disease

更新時間：2023-09-19

楊思雋Yang, Seu-Chun
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 13 years

Recruiting Trial

80Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊思雋

National Taiwan University Hospital

Division of Thoracic Medicine

List

18Cases

2024-11-01 - 2027-04-30

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-11-01 - 2027-03-20

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-03-31 - 2026-06-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-11-30 - 2027-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2018-02-01 - 2021-06-30

Phase III

A multicenter, randomized, double-blind, placebo-controlled, parallel-grouped Phase III trial to evaluate the efficacy and safety of Tezepelumab in adults and adolescents with poorly controlled severe asthma

  • Condition/Disease

    As an additional maintenance treatment for patients over 12 years old with severe asthma

  • Test Drug

    Tezepelumab

Participate Sites
4Sites

Terminated4Sites

2017-10-01 - 2023-05-31

Phase III

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)

  • Condition/Disease

    Stage IV, Metastatic Non-small Cell Lung Cancer

  • Test Drug

    Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-08-07 - 2021-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2014-02-01 - 2015-11-01

Phase III

A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia

  • Condition/Disease

    Community-Acquired Bacterial Pneumonia

  • Test Drug

    Solithromycin (CEM-101)

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB